L1 Retrotransposon RNA Modulation for Bone Mass and Aging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively addressed the role of L1 retrotransposons in contributing to tissue homeostasis and their potential impact on conditions such as osteoporosis and accelerated aging, particularly in modulating their activity in human cells.
Innovation Solution
Compositions and methods are developed to upregulate or downregulate L1 RNA activity using nucleic acids, expression vectors, and antisense oligonucleotides to manipulate L1 RNA levels in specific cell types, such as mesenchymal stem cells, to address conditions like osteoporosis and accelerated aging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If L1 retrotransposon activity is left unmodulated, then natural cellular functions and tissue homeostasis are maintained, but harmful effects including accelerated aging and osteoporosis occur
Solution Approach 1:
The patent applies parameter changes by modulating L1 retrotransposon activity through chemical compounds that alter the expression levels of L1 RNA and proteins. By changing the activity parameter of L1 elements, the invention reduces harmful effects such as accelerated aging and osteoporosis while maintaining beneficial tissue homeostasis functions.
Solution Approach 2:
The patent uses chemical compounds as intermediaries to modulate L1 retrotransposon activity. These compounds act as mediators between external control and the L1 elements, enabling selective modulation of L1 RNA and protein expression to achieve therapeutic effects without directly manipulating the retrotransposons themselves.
2Quantity of substance
If L1 RNA levels are increased to treat osteoporosis, then bone mass is improved, but uncontrolled retrotransposition may occur
Solution Approach 1:
The patent applies local quality by selectively modulating L1 activity in specific tissue contexts. The chemical compounds enable localized increase of L1 RNA levels in bone-related cells to improve bone mass, while controlling retrotransposition through mechanism-specific action that prevents harmful genomic integration elsewhere in the genome.
3Reliability
If chemical compounds are used to modulate L1 activity, then therapeutic effects are achieved, but complexity of treatment protocol increases
Solution Approach 1:
The patent employs small-molecule chemical compounds that can be administered as simple oral or injectable formulations. These discrete chemical agents provide reliable therapeutic effects through well-defined mechanisms, avoiding the complexity of gene therapy vectors, cell-based therapies, or multi-component systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modulation of L1 RNA levels enhances bone formation and reduces symptoms of osteoporosis and aging by increasing bone mass index and reducing cellular activity associated with accelerated aging.
Implementation Method 1
The L1 RNA can be downregulated by treating cells to downregulate L1 RNA levels. This step includes contacting the cells with one or more agents to inhibit L1 RNA. The L1 RNA inhibiting agent can be a nucleic acid, a peptide or a small molecule.
Data Source
AI summary
Compositions and methods for upregulating L1 RNA activity in a subject in need thereof are provided. The compositions include nucleic acids encoding L1 RNA or the L1 RNA, alone, or contained in an expression vector and/or further contained within osteogenic progenitor cells, for example, mesenchymal stem cells, genetically engineering to express L1 RNA. In this aspect, the compositions are used to increase L1 RNA levels for example, L1 RNA copy number in subjects in need of increasing their bone mass index. In a preferred embodiment, the bone progenitor cells are autologous cells.Compositions and methods for downregulating L1 RNA levels/activity in a subject in need thereof are also provided. The compositions include one or more agents in effective amounts to knockdown L1 RNA in a cell. The compositions can be used to treat conditions associated with ageing. A preferred agent is a L1 RNA antisense oligonucleotide.